A LEGACY OF SUCCESS
A RICH HISTORY WITH

45 Years of Experience

Our proprietary methodology ensures companies get the start they need to dramatically increase market value and provide the high rate of return their founders and investors deserve. Moreover, our healthcare focused Single Family Office specializes in building innovative companies that improve quality of care, quality of life, and healthcare economics worldwide.

 

Biotech/Pharma companies

1981
1986
1988
1990
1996
2004
2005
2007
2011
1981

1981

HYCOR - Monoclonal Antibodies. Founded with Dr. Paul Price and Dr. David Gordon who at the time, were co-directors of the Hybridoma Lab at the Centers for the Disease Control & Prevention (CDC). Gorlin financed company prior to $6 million IPO. Second Monoclonal company to go public.  Sold to Agilent for $100 million. Currently, subsidiary of Agilent.
1986

1986

THERAGENICS -Palladium implants for prostate cancer. Founded with Dr. John Russell, director of the Frank Neely Nuclear Research Center at Georgia Tech. Initially a privately financed company. Performed a reverse merger into a public shell value of $6 million. Managed from inception through sale. Reached market value of over $1 billion during Gorlin's involvement. NYSE: TGX
1988

1988

CytRx -Products to increase blood flow and dissolve clots for heart attacks and other blood vessel issues. Technology licensed from Emory University. Gorlin invested $200,000, raised additional funds and then took it public. The first IPO was $6 million. During Gorlin’s leadership, the company reached a market cap of over $200 million. NASDAQ: CYTR
1990

1990

MEDICIS -Dermatology.  The company was started with Gorlin's FDA attorney, Jonah Shacknai. It  began as an idea funded by Gorlin. Sold to Valeant Pharmaceuticals for $2.68 billion. The company is currently a subsidiary of Valeant.
1996

1996

EntreMed -Licensed anti-angiogenesis technology. This Technology was developed by Dr. Judah Folkman from Harvard Children’s Hospital. Reached a $1.4 billion market cap during involvement as Chairman. Sold to Casi Pharmaceuticals.
2004

2004

MEDIVATION -Drugs for refractory prostate cancer. Founded with Dr. David Hung. Gorlin loaned the money to start the company and took it public. The company was sold to Pfizer for $14 billion. NASDAQ: MDVN
2005

2005

MRI INTERVENTIONS -Platforms for minimally invasive surgical procedures in the brain and heart. Worked with Dr. Ali Rezhai of the Cleveland Clinic. Started the company and took it public. NASDAQ: MRIC
2007

2007

MiMedx - Innovative bioactive healing products for tissue regeneration. Founded the company. Is currently public with a market cap of $1.06 billion. NASDAQ: MDXG.
2011

2011

DARA Biosciences -Treatment for neuropathic pain and cancer. Mr. Gorlin started the company and invested $800,000 of Dara’s money in Medivation. He then distributed over half of Medivation's shares to Dara shareholders. Recently sold to Midatech Pharma.

Other companies

1990
1991
2001
2009
1990

1990

PermaFix -Environmental cleanup of nuclear waste. Gorlin started the company. Gorlin sold his interest when the company was valued in excess of $100 million. NASDAQ: PEFI

1991

Pretty Good Privacy Business encryption software. Worked with son and Phil Zimmerman and raised all of the funding. Two years after founding, sold to Network Associates, Inc. for $38 million. Network Associates sold to Symantec in 2010.
2001

2001

Judicial Correction Services -Private probation services. Helped son start the company; raised the initial funds. Sold to Correctional Healthcare for a return to investors of 3-5 times their initial investment. In 2014 it was acquired by Correct Care, LLC.
2009

2009

Kabbage -Loans for small businesses.  Mr. Gorlin assisted his son, Marc Gorlin, in starting the company. Currently, the company loans over $1 billion a year and is valued by major investment banks at $800 million to $1 billion.

PORTFOLIO
Building Wealth for Investors.
Improving Quality of Life for All.
feature-img-4
HYCOR

1981 HYCOR - Monoclonal Antibodies.  Founded with Dr. Paul Price and Dr. David Gordon who at the time, were co-directors of the Hybridoma Lab at the Centers for the Disease Control & Prevention (CDC). Gorlin financed company prior to $6 million IPO. Second Monoclonal company to go public.  Sold to Agilent for $100 million. Currently, subsidiary of Agilent. (http://www.hycorbiomedical.com)

THERAGENICS

1986 THERAGENICS -Palladium implants for prostate cancer. Founded with Dr. John Russell, director of the Frank Neely Nuclear Research Center at Georgia Tech. Initially a privately financed company. Performed a reverse merger into a public shell value of $6 million. Managed from inception through sale. Reached market value of over $1 billion during Gorlin's involvement. NYSE: TGX

CytRx

1988 CytRx -Products to increase blood flow and dissolve clots for heart attacks and other blood vessel issues. Technology licensed from Emory University. Gorlin invested $200,000, raised additional funds and then took it public. The first IPO was $6 million. During Gorlin’s leadership, the company reached a market cap of over $200 million. NASDAQ: CYTR  (http://www.cytrx.com)

MEDICIS

1990 MEDICIS -Dermatology.  The company was started with Gorlin's FDA attorney, Jonah Shacknai. It  began as an idea funded by Gorlin. Sold to Valeant Pharmaceuticals for $2.68 billion. The company is currently a subsidiary of Valeant. (http://www.valeant.com)

 

 

EntreMed

1996 EntreMed -Licensed anti-angiogenesis technology. This Technology was developed by Dr. Judah Folkman from Harvard Children’s Hospital. Reached a $1.4 billion market cap during involvement as Chairman. Sold to Casi Pharmaceuticals. (http://www.casipharmaceuticals.com)

 

MEDIVATION

2004 MEDIVATION -Drugs for refractory prostate cancer. Founded with Dr. David Hung. Gorlin loaned the money to start the company and took it public. The company was sold to Pzizer for $14 billion. NASDAQ: MDVN  (http://www.medivation.com)

 

 

MRI INTERVENTIONS

2005 MRI INTERVENTIONS -Platforms for minimally invasive surgical procedures in the brain and heart. Worked with Dr. Ali Rezhai of the Cleveland Clinic. Started the company and took it public. NASDAQ: MRIC (http://www.mriinterventions.com)

MiMedx

2007 MiMedx - Innovative bioactive healing products for tissue regeneration. Founded the company. Is currently public with a market cap of $1.06 billion. NASDAQ: MDXG. (http://www.mimedx.com)

 

DARA Biosciences

2011 DARA Biosciences -Treatment for neuropathic pain and cancer.Gorlin started the company and invested $800,000 of Dara’s money in Medivation. He then distributed over half of Medivation's shares to Dara shareholders. Recently sold to Midatech Pharma. (http://www.darabio.com)

PermaFix

1990 PermaFix -Environmental cleanup of nuclear waste. Gorlin started the company. Gorlin sold his interest when the company was valued in excess of $100 million. NASDAQ: PEFI  (http://www.perma-fix.com)

1991 Pretty Good Privacy Business encryption software. Worked with son and Phil Zimmerman and raised all of the funding. Two years after founding, sold to Network Associates, Inc. for $38 million. Network Associates sold to Symantec in 2010. (https://www.symantec.com)

Judicial Correction Services

2001 Judicial Correction Services -Private probation services. Helped son start the company; raised the initial funds. Sold to Correctional Healthcare for a return to investors of 3-5 times their initial investment. In 2014 it was acquired by Correct Care, LLC. (http://www.correctcaresolutions.com)

Kabbage

2009 Kabbage -Loans for small businesses.  Mr. Gorlin assisted his son, Marc Gorlin, in starting the company. Currently, the company loans over $1 billion a year and is valued by major investment banks at $800 million to $1 billion. (https://www.kabbage.com)

GET IN TOUCH

Contact Us

Alpine Bank Building. 600 E. Hopkins Ave., #302. Aspen CO 81611
agardner@gorlincompanies.com

to top button